State Board of Administration of Florida Retirement System continued to hold its stake in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 24,308 shares of the company’s stock at the end of the second quarter. State Board of Administration of Florida Retirement System owned about 0.06% of Pacira Pharmaceuticals worth $1,159,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. BlackRock Inc. grew its position in Pacira Pharmaceuticals by 28,922.7% during the first quarter. BlackRock Inc. now owns 3,183,787 shares of the company’s stock worth $145,180,000 after buying an additional 3,172,817 shares during the period. Vanguard Group Inc. grew its position in shares of Pacira Pharmaceuticals by 4.1% in the first quarter. Vanguard Group Inc. now owns 2,860,092 shares of the company’s stock valued at $130,420,000 after purchasing an additional 112,853 shares during the last quarter. Westfield Capital Management Co. LP grew its position in shares of Pacira Pharmaceuticals by 0.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,608,847 shares of the company’s stock valued at $73,363,000 after purchasing an additional 5,166 shares during the last quarter. State Street Corp grew its position in shares of Pacira Pharmaceuticals by 2.7% in the first quarter. State Street Corp now owns 1,107,356 shares of the company’s stock valued at $50,499,000 after purchasing an additional 28,663 shares during the last quarter. Finally, Macquarie Group Ltd. grew its position in shares of Pacira Pharmaceuticals by 6.7% in the first quarter. Macquarie Group Ltd. now owns 1,074,770 shares of the company’s stock valued at $49,010,000 after purchasing an additional 67,321 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: “Pacira Pharmaceuticals, Inc. (PCRX) Stake Maintained by State Board of Administration of Florida Retirement System” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/pacira-pharmaceuticals-inc-pcrx-stake-maintained-by-state-board-of-administration-of-florida-retirement-system/1574745.html.

In other Pacira Pharmaceuticals news, Director Paul J. Hastings sold 1,044 shares of the business’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $36.15, for a total value of $37,740.60. Following the sale, the director now owns 3,518 shares of the company’s stock, valued at approximately $127,175.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Kristen Marie Williams sold 3,461 shares of the business’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $36.75, for a total transaction of $127,191.75. Following the completion of the sale, the chief accounting officer now directly owns 21,312 shares in the company, valued at approximately $783,216. The disclosure for this sale can be found here. Insiders have sold 33,390 shares of company stock worth $1,215,480 in the last ninety days. 6.60% of the stock is currently owned by insiders.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) opened at 35.70 on Wednesday. The firm’s 50-day moving average is $36.91 and its 200 day moving average is $44.24. The firm’s market capitalization is $1.44 billion. Pacira Pharmaceuticals, Inc. has a one year low of $29.95 and a one year high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.06). Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The company had revenue of $70.90 million for the quarter, compared to the consensus estimate of $73.37 million. During the same period last year, the firm posted $0.21 EPS. The company’s revenue was up 1.9% compared to the same quarter last year. Analysts forecast that Pacira Pharmaceuticals, Inc. will post ($0.17) EPS for the current fiscal year.

PCRX has been the topic of several research reports. Canaccord Genuity set a $56.00 price target on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, July 25th. Mizuho reaffirmed a “buy” rating and set a $54.00 price target on shares of Pacira Pharmaceuticals in a research note on Wednesday, July 26th. Royal Bank Of Canada set a $58.00 price target on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, June 27th. HC Wainwright set a $59.00 price target on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, Needham & Company LLC started coverage on shares of Pacira Pharmaceuticals in a research note on Tuesday, August 22nd. They set a “buy” rating and a $55.00 price target on the stock. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $52.92.

Pacira Pharmaceuticals Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.